Anaptysbio, INC Form 4 insider transactions

AnaptysBio CEO Daniel Faga reported the acquisition of shares from RSU vesting and a subsequent 'sell to cover' transaction for tax obligations.

AnaptysBio's CFO, Dennis Mulroy, sold 3,363 shares of common stock at $43.26 to cover tax withholding obligations related to restricted stock unit vesting.

AnaptysBio's Chief Medical Officer, Paul F. Lizzul, reported the acquisition of common stock from RSU vesting and a subsequent 'sell to cover' transaction for tax purposes.

AnaptysBio's Chief Legal Officer, Eric J. Loumeau, sold 2,983 shares of common stock for $43.26 per share to cover tax withholding obligations following the vesting of restricted stock units.

AnaptysBio director J. Anthony Ware sold 3,900 shares of common stock for approximately $193,342.50 on December 23, 2025.

Director John P. Schmid disclosed an indirect sale of 11,068 ANAB shares at $51 via an ESOP and continues to hold 52,267 shares directly.

AnaptysBio's Chief Medical Officer, Paul F. Lizzul, exercised stock options and subsequently sold 1,500 shares of common stock under a pre-arranged trading plan.

AnaptysBio's Chief Financial Officer, Dennis Mulroy, exercised stock options and subsequently sold 10,000 shares of common stock for a significant gain.

AnaptysBio's Chief Legal Officer, Eric J. Loumeau, exercised stock options and subsequently sold 10,000 shares of common stock for $51 per share, as part of a pre-arranged 10b5-1 trading plan.

AnaptysBio's Chief Legal Officer, Eric J. Loumeau, executed pre-planned option exercises and subsequent sales of company common stock.

AnaptysBio CFO Dennis Mulroy exercised stock options and sold a portion of his common stock holdings under a pre-arranged 10b5-1 trading plan.

ANAPTYSBIO's Chief Legal Officer, Eric J. Loumeau, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 trading plan.

ANAPTYSBIO Director John A. Orwin converted 1,300 restricted stock units into common stock, increasing his direct holdings to 10,665 shares.

AnaptysBio Director Hollings Renton exercised stock options and sold a portion of the resulting common stock shares under a pre-arranged 10b5-1 trading plan.

AnaptysBio Director Hollings Renton exercised 20,925 stock options at $6.93 and simultaneously sold all acquired shares for a weighted average price of approximately $23.49, generating over $348,000 in proceeds, as part of a pre-arranged trading plan.

AnaptysBio, Inc. Director Dennis M. Fenton sold 3,015 shares of common stock for $23.97 per share on June 18, 2025, as part of a pre-arranged 10b5-1 trading plan to satisfy tax liabilities from restricted stock unit vesting.

AnaptysBio Director Hollings Renton sold 3,015 shares of common stock at $23.97 per share on June 18, 2025, to satisfy tax obligations related to the vesting of restricted stock units.

AnaptysBio, Inc. Director Rita Jain converted 7,330 Restricted Stock Units (RSUs) into common stock on June 15, 2025, as part of her compensation plan.

AnaptysBio, Inc. Director Dennis M. Fenton acquired 6,030 shares of common stock through the vesting of restricted stock units on June 15, 2025, increasing his direct beneficial ownership to 7,980 shares.

AnaptysBio, Inc. Director Magda Marquet has increased her direct beneficial ownership by 6,030 shares of common stock following the conversion of restricted stock units.

AnaptysBio, Inc. Director John A. Orwin has acquired 6,030 shares of common stock through the vesting of restricted stock units, as reported in a recent SEC Form 4 filing.

AnaptysBio, Inc. Director Hollings Renton has acquired 6,030 shares of common stock through the vesting of restricted stock units, increasing his direct beneficial ownership to 7,980 shares.

AnaptysBio, Inc. Director John P. Schmid has converted 6,030 Restricted Stock Units (RSUs) into common stock, increasing his direct beneficial ownership.

ANAPTYSBIO, Inc. Director J. Anthony Ware converted 6,030 restricted stock units into common shares on June 15, 2025, increasing his direct beneficial ownership to 13,530 shares.

Director John P. Schmid reports acquisition of AnaptysBio shares through the company's Employee Ownership Plan.

John P. Schmid, a director at AnaptysBio, Inc., exercised stock options expiring in 2025, acquiring a total of 42,337 shares of common stock.

AnaptysBio's Chief Medical Officer, Paul F. Lizzul, reported multiple transactions involving company stock and restricted stock units, including acquisitions and disposals to cover tax obligations.

AnaptysBio's Chief Financial Officer, Dennis Mulroy, has reported multiple transactions involving the company's stock, including the vesting of restricted stock units and the acquisition of shares through the employee stock purchase plan.

Eric Loumeau, Chief Legal Officer of AnaptysBio, reports the acquisition and disposal of common stock and restricted stock units related to vesting and tax obligations.

Director Dennis M. Fenton acquired stock options and restricted stock units in AnaptysBio, Inc. on January 7, 2025.